Crystalys Therapeutics Welcomes Justin Thacker as CFO to Lead Phase 3 Trials of Dotinurad Crystalys Therapeutics has announced the appointment of Justin Thacker as CFO. His experience is vital for the advancement of Dotinurad in Phase 3 trials.

Crystalys Therapeutics Welcomes Justin Thacker as CFO to Lead Phase 3 Trials of Dotinurad #USA #San_Diego #Crystalys_Therapeutics #dotinurad #Justin_Thacker